2. Search Result
Search Result
Results for "

refractory

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

2

Peptides

16

Inhibitory Antibodies

1

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109170
    Eliapixant

    BAY 1817080

    		 P2X Receptor Inflammation/Immunology
    Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough .
    Eliapixant
  • HY-109068
    Parsaclisib

    INCB050465; IBI-376

    		 PI3K Cancer
    Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies .
    Parsaclisib
  • HY-109068A
    Parsaclisib hydrochloride

    INCB050465 hydrochloride; IBI-376 hydrochloride

    		 PI3K Cancer
    Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies .
    Parsaclisib hydrochloride
  • HY-P5535
    Invopressin

    OCE-205

    		 Vasopressin Receptor Inflammation/Immunology
    Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC50: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites .
    Invopressin
  • HY-109117
    Iadademstat

    ORY-1001

    		 Histone Demethylase Cancer
    Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .
    Iadademstat
  • HY-144858
    EZM0414
    3 Publications Verification

    		 Histone Methyltransferase Cancer
    EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
    EZM0414
  • HY-136026
    Camlipixant

    BLU-5937

    		 P2X Receptor Inflammation/Immunology
    Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC50 of 25 nM against hP2X3 homotrimeric. Camlipixant shows potent anti-tussive effect and no taste alteration. Camlipixant can be used for the research of unexplained, refractory chronic cough .
    Camlipixant
  • HY-P99033
    Mosunetuzumab

    BTCT-4465A

    		 CD20 CD3 Inflammation/Immunology Cancer
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
    Mosunetuzumab
  • HY-16215
    Mipsagargin

    G-202

    		 Drug-Linker Conjugates for ADC Cancer
    Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .
    Mipsagargin
  • HY-14572
    PR-104A

    SN 27858

    		 DNA Alkylator/Crosslinker Drug Metabolite Cancer
    PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity . PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) .
    PR-104A
  • HY-121877
    Valnoctamide
    1 Publications Verification

    Valmethamide

    		 GABA Receptor Neurological Disease
    Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on GABAA receptors .
    Valnoctamide
  • HY-120355A
    AP14145 hydrochloride

    		Potassium Channel Cardiovascular Disease
    AP14145 hydrochloride is a potent KCa2 (SK) channel negative allosteric modulator with an IC50 of 1.1 μM for KCa2.2 (SK2) and KCa2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF) .
    AP14145 hydrochloride
  • HY-114306
    EC0489

    		Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
    EC0489
  • HY-B0772A
    Nifekalant hydrochloride

    MS-551

    		 Potassium Channel Cardiovascular Disease
    Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC50 of 10 µM. Nifekalant hydrochloride can be used for refractory ventricular tachyarrhythmias research .
    Nifekalant hydrochloride
  • HY-121877S
    Valnoctamide-d5

    		Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Valnoctamide-d5 is the deuterium labeled Valnoctamide. Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on GABAA receptors[1][2].
    Valnoctamide-d5
  • HY-P9989
    Linvoseltamab

    REGN5458

    		 CD3 TNF Receptor Cancer
    Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .
    Linvoseltamab
  • HY-P99100
    Visugromab

    CTL-002

    		 PD-1/PD-L1 Cancer
    Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
    Visugromab
  • HY-109108
    Valemetostat
    1 Publications Verification

    DS-3201

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
    Valemetostat
  • HY-109108A
    Valemetostat tosylate
    1 Publications Verification

    DS-3201 tosylate

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
    Valemetostat tosylate
  • HY-116392B
    DL-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .
    DL-threo-PDMP hydrochloride
  • HY-19589
    JTS-653

    JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents .
    JTS-653
  • HY-P99466
    Begelomab

    SAND-26

    		 Dipeptidyl Peptidase Inflammation/Immunology
    Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .
    Begelomab
  • HY-P99453
    Azintuxizumab

    		ADC Antibody Cancer
    Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM) .
    Azintuxizumab
  • HY-119264A
    PRLX-93936 dihydrochloride

    		HIF/HIF Prolyl-Hydroxylase Ras Cancer
    PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma .
    PRLX-93936 dihydrochloride
  • HY-B0615A
    Moricizine Hydrochloride

    EN 313; Ethmozin; Moracizine
    Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .
    Moricizine Hydrochloride
  • HY-160038
    GAC0003A4

    		LXR Cancer
    GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies .
    GAC0003A4
  • HY-153939S
    Idasanutlin-d3-1

    RG7388-d3-1

    		 Isotope-Labeled Compounds Cancer
    Idasanutlin-d3-1 (RG7388-d3-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of MDM2/p53. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .
    Idasanutlin-d3-1
  • HY-147413
    Unecritinib

    TQ-B3101

    		 EGFR Cancer
    Unecritinib (TQ-B3101) is a potent EGFR tyrosine kinase inhibitor. Unecritinib shows anticancer activity. Unecritinib inhibits ALK, ROS1, and MET. Unecritinib has the potential for the research of solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma .
    Unecritinib
  • HY-P99056
    Utomilumab

    PF 05082566

    		 TNF Receptor Inflammation/Immunology Cancer
    Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 + non-Hodgkin lymphomas (NHL) .
    Utomilumab
  • HY-P99338
    Tisagenlecleucel

    CTL019

    		 CD19 Inflammation/Immunology Cancer
    Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
    Tisagenlecleucel
  • HY-139481
    TL-895

    		Btk Infection Cancer
    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively . TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research .
    TL-895
  • HY-P99378
    Neihulizumab

    ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)

    		 Apoptosis Inflammation/Immunology
    Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
    Neihulizumab
  • HY-10224A
    Panobinostat lactate

    LBH589 lactate; NVP-LBH589 lactate

    		 HDAC HIV Autophagy Apoptosis Infection Cancer
    Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .
    Panobinostat lactate
  • HY-P99730
    Mezagitamab

    TAK-079

    		 CD38 Cancer
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
    Mezagitamab
  • HY-112037
    IACS-010759
    5+ Cited Publications

    IACS-10759

    		 Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .
    IACS-010759
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d8; Ethmozin-d8; Moracizine-d8

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].
    Moricizine-d8(Hydrochloride)
  • HY-122347A
    Orvepitant maleate

    GW823296 maleate

    		 Neurokinin Receptor Neurological Disease
    Orvepitant maleate (GW823296 maleate) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pKi of 10.2 for human neurokinin-1 receptor. Orvepitant maleate can across the blood-brain barrier. Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatment .
    Orvepitant maleate
  • HY-114372
    Lycopodine

    		Lipoxygenase Caspase Apoptosis Cancer
    Lycopodine, a pharmacologically important bioactive component derived from Lycopodium clavatumspores, triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in refractory prostate cancer cells without modulating p53 activity . Lycopodine inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation .
    Lycopodine
  • HY-112037A
    IACS-010759 hydrochloride
    5+ Cited Publications

    IACS-10759 hydrochloride

    		 Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .
    IACS-010759 hydrochloride
  • HY-108579
    UCL 1684 dibromide

    		Potassium Channel Cardiovascular Disease
    UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of INa. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .
    UCL 1684 dibromide
  • HY-17611
    Etripamil

    MSP-2017; (-)-MSP-2017

    		 Calcium Channel Cardiovascular Disease
    Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells .
    Etripamil
  • HY-P99107
    Brentuximab vedotin

    		Antibody-Drug Conjugates (ADCs) Apoptosis TNF Receptor Cancer
    Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma .
    Brentuximab vedotin
  • HY-P99167
    Lucatumumab

    HCD122

    		 TNF Receptor Cancer
    Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
    Lucatumumab
  • HY-101563
    GSK3326595
    10+ Cited Publications

    EPZ015938

    		 Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595
  • HY-P99024
    Glofitamab

    RO7082859

    		 CD20 Cancer
    Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .
    Glofitamab
  • HY-161279
    Antibiofilm agent-5

    		Bacterial Lactate Dehydrogenase Reactive Oxygen Species Infection
    Antibiofilm agent-5 (compound 6c) is a multitargeting antibacterial agent with potent antibiofilm activity. Antibiofilm agent-5 could induce metabolic dysfunction by deactivating lactate dehydrogenase and promote the accumulation of reactive oxygen species to decrease the reduced glutathione and ultimately cause oxidative damage in bacteria. Antibiofilm agent-5 can be used for the research of refractory biofilm-intensified bacterial infections .
    Antibiofilm agent-5
  • HY-10446
    Pralatrexate
    4 Publications Verification

    		 Antifolate Apoptosis Cancer
    Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pralatrexate
  • HY-P99740
    Mirzotamab

    		CD276/B7-H3 Cancer
    Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
    Mirzotamab
  • HY-107753
    XRP44X

    		Ras Inflammation/Immunology Cancer
    XRP44X inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2 . XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules .
    XRP44X
  • HY-119874
    Alkannin

    		Pyruvate Kinase Inflammation/Immunology Cancer
    Alkannin is a potent and specific inhibitor of tumor-specific pyruvate kinase-M2 (PKM2). Alkannin does not inhibit PKM1 and pyruvate kinase-L (PKL). Alkannin acts as a potential anticancer agent .
    Alkannin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: